| Literature DB >> 34163856 |
Sarah-Jane Richards1, Tessa Keenan2, Jean-Baptiste Vendeville3, David E Wheatley3, Harriet Chidwick2, Darshita Budhadev2, Claire E Council3, Claire S Webster4, Helene Ledru4, Alexander N Baker1, Marc Walker5, M Carmen Galan4, Bruno Linclau3, Martin A Fascione2, Matthew I Gibson1,6.
Abstract
Galectins are potential biomarkers and therapeutic targets. However, galectins display broad affinity towards β-galactosides meaning glycan-based (nano)biosensors lack the required selectivity and affinity. Using a polymer-stabilized nanoparticle biosensing platform, we herein demonstrate that the specificity of immobilised lacto-N-biose towards galectins can be 'turned on/off' by using site-specific glycan fluorination and in some cases reversal of specificity can be achieved. The panel of fluoro-glycans were obtained by a chemoenzymatic approach, exploiting BiGalK and BiGalHexNAcP enzymes from Bifidobacterium infantis which are shown to tolerate fluorinated glycans, introducing structural diversity which would be very laborious by chemical methods alone. These results demonstrate that integrating non-natural, fluorinated glycans into nanomaterials can encode unprecedented selectivity with potential applications in biosensing. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 34163856 PMCID: PMC8179109 DOI: 10.1039/d0sc05360k
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.825
Fig. 1(A) Chemical syntheses of fluorinated acceptors. (B) Fluorinated lacto-N-biose analogues prepared using a chemoenzymatic strategy with BiGalK and BiGalHexNAcP. TFA = trifluoroacetyl.
Fig. 2Nanoparticle synthesis and characterization. (A) Synthetic route to conjugate fluoro-glycans onto nanoparticles; (B) UV-Vis traces of all nanoparticles showing colloidal stability; (C) dynamic light scattering (DLS) of all nanoparticles showing size increase upon polymer coating.
Fig. 3Screening of lectin/F-GlycoNP binding. (A) Schematic of aggregation assay; (B) dose–response to Soybean agglutinin (SBA); (C) dose–response to Galectin-3; (D) aggregation kinetics with Galectin-3; (E) dynamic light scattering with Galectin-3.
Fig. 4Biolayer interferometry analysis of binding of AuNPs to Galectin-3. (A) Lacto-N-biose (15); (B) 3FGal-β(1,3)-GlcNAc (16); (C) Gal-β(1,3)-6FGlcNTFA (20); (D) 6FGal-β(1,3)-6FGlcNTFA (21).
Fig. 5Galectin-7 binding to the F-glyconanoparticle library. (A) Dose–response curve for the AuNP aggregation assay; (B) summary of apparent KD (nM) for selected glycans showing the fine-tuning and selectivity inversion. (−) = no binding.